NCI selects Emory for national network focused on cancer therapeutic discovery

A research team led by Haian Fu, PhD, within the cancer genomics center at Emory University and Winship Cancer Institute, has been selected by the National Cancer Institute (NCI) to participate in an elite national network focused on discovery of new cancer targets and precision cancer therapies.

The Emory Molecular Interaction Center for Functional Genomics (MicFG) will be funded by a $4.52 million grant over five years. It is one of 12 centers designated for the NCI's Cancer Target Discovery and Development (CTD2) Network. Emory was first chosen by the NCI for its CTD2 Network in 2012. The CTD2 initiativewas established to advance the knowledge of cancer etiology and mechanisms, and to potentially accelerate the development of therapeutic targets for precision oncology using computational and functional genomic approaches.

The Emory CTD2 Center will focus on networks of protein-protein interactions created by mutated residues in oncogenes and tumor suppressors found in patient tumors. These unique protein-protein interactions could become tumor-specific targets for cancer drug development.

Dr. Fu, who is a CB and MSP faculty member, is Winship Partner in Research Endowed Chair, professor and chair of pharmacology, professor of hematology and medical oncology, and associate dean for innovation and international strategies at Emory University School of Medicine. He also directs the Emory Chemical Biology Discovery Center and he serves as leader of Winship's Discovery & Developmental Therapeutics Program. Among the co-investigators are genomics and bioinformatics experts Wei Zhou, PhD, a CB and GMB faculty member; Carlos S. Moreno, PhD, a CB and GMB faculty member; and Lee Cooper, PhD, a CB faculty member.

Click here to view the full story in the Emory News Center.